Dimitrios Mougiakakos

Medizinische Fakultät Professur für CAR-T-Zell-Therapie Professur für Hämatologie mit dem Schwerpunkt Zelluläre Immuntherapie

Successful Generation of CD19 Chimeric Antigen Receptor T Cells from Patients with Advanced Systemic Lupus Erythematosus (2022) Kretschmann S, Völkl S, Reimann H, Krönke G, Schett G, Achenbach S, Lutzny-Geier G, et al. Journal article Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience (2022) Dreger P, Holtick U, Subklewe M, von Tresckow B, Ayuk F, Wagner E, Wulf G, et al. Journal article Bone marrow stroma cells promote induction of a chemoresistant and prognostic unfavorable S100A8/A9high AML cell subset. (2022) Böttcher M, Panagiotidis K, Bruns H, Stumpf M, Völkl S, Geyh S, Dietel B, et al. Journal article Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus (2022) Mackensen A, Müller F, Mougiakakos D, Böltz S, Wilhelm A, Aigner M, Völkl S, et al. Journal article The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. (2022) Rejeski K, Perez A, Iacoboni G, Penack O, Bucklein V, Jentzsch L, Mougiakakos D, et al. Journal article CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma (2021) Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, Mougiakakos D, et al. Journal article Late Non-Relapse Mortality (NRM) after Standard-of-Care (SOC) CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Frequency, Causes, and Risk Factors.a GLA/DRST Real World Analysis (2021) Dreger P, Schubert ML, Holtick U, Subklewe M, Von Bastian T, Ayuk FA, Wagner EM, et al. Conference contribution Standard of Care CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Does Bridging Efficacy Matter? a German GLA/DRST Real World Analysis (2021) Bethge WA, Martus P, Schmitt M, Holtick U, Borchmann P, Subklewe M, Rejeski K, et al. Conference contribution The CAR- Hematotox Identifies Patients at High Risk for Prolonged Neutropenia, Infectious Complications and Prolonged Hospitalization Following CD19-CART in R/R LBCL (2021) Rejeski K, Perez-Perez A, Iacoboni G, Penack O, Buecklein VL, Jentzsch L, Mougiakakos D, et al. Conference contribution Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia (2021) Jetani H, Navarro-Bailón A, Maucher M, Frenz S, Verbruggen C, Yeguas A, Vidriales MB, et al. Journal article